175
Views
0
CrossRef citations to date
0
Altmetric
Commentaries

Is it time to use minimal residual disease to stratify post-remission treatment for acute myeloid leukemia?

&
Pages 3005-3007 | Published online: 19 Jun 2015
 

Acknowledgments

Dr Liu served on one advisory board meeting for MedImmune/Astra Zeneca. Dr. Liu is supported by grant from Cancer Research Foundation and K12 Paul Calabresi Career Development in Clinical Oncology Award.

Potential conflict of interest

Disclosure forms provided by the authors are available with the full text of this article at www.informahealthcare.com/lal.

Log in via your institution

Log in to Taylor & Francis Online

PDF download + Online access

  • 48 hours access to article PDF & online version
  • Article PDF can be downloaded
  • Article PDF can be printed
USD 65.00 Add to cart

Issue Purchase

  • 30 days online access to complete issue
  • Article PDFs can be downloaded
  • Article PDFs can be printed
USD 1,065.00 Add to cart

* Local tax will be added as applicable

Related Research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.